ABSTRACT

Purpose: Pigment epithelial detachment (PED) may be seen in all stages of age-related macular degeneration (ARMD) and may lead to poor prognosis. In this study, we retrospectively examined the effect of anti-VEGF treatments in ARMD patients with vascularized PED.

Methods: Medical records of 15 patients with PED secondary to ARMD were reviewed retrospectively. The diagnosis of PED was made with fundoscopy, fundus fluorescein angiography and optical coherence tomography. Patients were treated with intravitreal ranibizumab or/and bevacizumab and followed up for a minimum of one year. PED height and best corrected visual acuity (BCVA) was obtained before the first intravitreal anti-VEGF injection and again at the 1st, 3rd, 6th and 12th month after the injection.

Results: The mean baseline BCVA was 0.71 ± 0.48 logarithm of the minimal angle of resolution (logMAR) unit and the mean baseline PED height was 361 ± 153 µ. The mean injection count per eye was 3.9 ± 2.9. There was a significant reduce in mean PED height (247 ± 177 µ) also in 2 eyes PED completely resolved at the end of the follow up period. The mean BCVA at 12th month (0.69 ± 0.37) were not different from the baseline record.

Conclusions: This retrospective case series showed that intravitreal anti-VEGF therapy preserved vision and reduced PED height in PED patients in a one-year follow-up period.

Keywords: Vascular endothelial growth factor A/antagonists & inhibitors; Retinal pigment epithelium/pathology; Retinal detachment; Macular degeneration/drug therapy; Aged

INTRODUCTION

Age-related macular degeneration (ARMD) is a very common cause of vision loss especially in elderly patients living in developed countries[1]. ARMD is caused by the accumulation of drusen in the macula, which is the most important part of the retina, and this process ends in serious irreversible visual impairment. Pigment epithelial detachment (PED) may be seen in all stages of ARMD and may lead to poor prognosis because of retina pigment epithelial (RPE) tears, submacular haemorrhage and, finally, disciform scars[2,3]. ANCHOR and MARINA studies showed that the vascular endothelial growth factor inhibitor (anti-VEGF), ranibizumab, was effective in the treatment of neovascular ARMD and repeated injections improved or preserved visual acuity (VA)[4,5]. However, these large studies did not provide specific information about ARMD patients with PED. In this study, we retrospectively examined the effect of anti-VEGF treatments in ARMD patients with vascularized PED.

METHODS

This retrospective study was performed in the Department of Ophthalmology at the University of Dicle School of Medicine. The study was approved by the local ethics committee at Dicle University. The medical records of patients with ARMD were reviewed and abstracted between January 2008 and December 2012. The demographic and clinical characteristics of the patients were recorded.

The diagnosis of PED was made with fundoscopy, fundus fluorescein angiography (FA) and optical coherence tomography (OCT) (Stratus, Carl Zeiss Meditec, Dublin, CA)[6,7].

Funding: No specific financial support was available for this study.

Disclosure of potential conflicts of interest: H. Yüksel, None; F. M. Türkcü, None; A. Ş. Şahin, None; M. Şahin, None; Y. Çinar, None; A. K. Çiğit, None; S. Arı, None; I. Çaça, None.

Correspondence address: Harun Yüksel. Dicle Üniversitesi Tıp Fakültesi, Sun/Diyarbakir, Turkey - E-mail: harunyukssel@gmail.com
In this study, the patients were treated with ranibizumab (Lucentis; Genetech Inc., South San Francisco, CA, USA) or/and bevacizumab (Avastin, Genentech, South San Francisco, CA, USA) and followed up for a minimum of one year. Baseline best corrected visual acuity (BCVA) was obtained before the first intravitreal anti-VEGF injection (V0) and again at the 1st (V1), 3rd (V3), 6th (V6) and 12th (V12) months after the injection, using the Snellen chart. The treatment modalities used on the patients were also recorded. BCVA was converted to a logarithm of the minimal angle of resolution (logMAR units) for analysis. PED heights were measured during the same visits and noted as PED0, PED1, PED3, PED6 and PED12. PED height was measured from the scanned image using the Proportional Process Report Software in the OCT device (Carl Zeiss Meditec, Dublin, CA), using the method described by Chan et al. (Figure 1). The following exclusion criteria were used: intravitreal triamcinolone (IVTA) injection, photodynamic therapy (PDT), laser photocoagulation, glaucoma, associated retinal disease, cataract surgery and loss to follow-up.

Results are presented as mean ± standard deviation (Range). Friedman and Wilcoxon tests were used for statistic analysis of changes in PED height and BCVA. A p-value less than 0.05 was considered statistically significant.

**RESULTS**

The medical records of 324 patients were evaluated between January 2008 and December 2012. Fifteen patients were eligible for the study (9 males). The mean age of the patients was 70.9 ± 5.5 (61-77) years. Nine of 15 eyes also had intraretinal fluid and four of these nine eyes had also RPE tears. The mean injection count per eye was 3.9 ± 2.9 (1-9). Twelve patients received only ranibizumab (n=6) or bevacizumab (n=6) and three patients received both treatments. Three of the patients with RPE tears received ranibizumab and another three received bevacizumab.

In the group, the mean V0 was 0.71 ± 0.48 logMAR units and the mean PED0 was 361 ± 153 µ. In follow-up visits there was no statistically significant decrease or increase in the mean BCVA (Figure 2). The mean PED3 and PED12 were lower than the baseline PED height (p=0.003, p=0.009, respectively, Table 1). At the end of the follow-up period, PED completely resolved only in two patients. Neither systemic nor local adverse effects, like uveitis, cataract formation, glaucoma or endophthalmitis, were observed throughout the follow-up period.

**DISCUSSION**

It is very difficult to treat patients with ARMD that is also accompanied by PED. The eyes of these patients often have poor prognosis. The pathogenesis of PED in ARMD is explained by age-related changes in Bruch’s membrane. In elderly patients, Bruch’s membrane thickens due to the accumulation of lipids and abnormal materials. This accumulation results in reduced hydraulic conductivity of the Bruch’s membrane-chorioid complex, which leads to a decreased capacity for fluid exchange between the choroidal and retinal pigment epithelial compartments.

Anti-VEGF drugs are thought to be effective in treating PED because they reduce vascular RPE permeability. Bevacizumab and ranibizumab have been efficacious for treating various types of retinal vascular diseases. Intravitreal injection of those drugs was shown to be effective in diabetic and veno-occlusive macular edema and ARMD.

In our study, we investigated the BCVA and PED height of patients with pigment epithelial detachments due to ARMD, who were treated with anti-VEGF agents over the course of one year. An average 3.9 ± 2.9 (1-9) injections were performed on patients. Repeated injections of ranibizumab and bevacizumab provided a stable BCVA and reduced PED height, despite the fact that PED was not completely resolved in most of patients at the end of one year.

Many treatments, such as laser photocoagulation and PDT have been used to treat PED that is associated with ARMD. In PDT studies, it has been reported that the VA of patients did not increase and that, in some cases, the patient’s VA decreased due to the development of RPE tears, depending on the treatment or the natural course of the disease. Consequently, on the basis of the association between PED and inflammation, IVTA treatment was added to the PDT. However, that treatment resulted in complications, such as glaucoma and cataracts.

Lommatsch et al. reported that anti-VEGF agents are the most effective treatment for PED. In their study, they found that anti-VEGF agents were more effective in the treatment of PED due to ARMD than triamcinolone acetonide combined PDT therapy. Similar to our study, Chen et al. reported stable or increased vision in PED patients, secondary to ARMD, when treated with intravitreal bevacizumab in an average follow-up period of 30 weeks, despite the continuation of PED. However, Ritter et al. reported that reduction of PED height was significant at the 6th month mark, but it was not maintained for one year in PED patients treated with anti-VEGF.
The lack of vision increase was thought to be the result of a loss of function in the photoreceptors due to the presence of long-term RPE detachment and RPE tears in some of the patients. RPE tears, which were seen in four (27%) of our cases, are one of the most important factors affecting VA in patients with PED. RPE tears either appear at the time of admission or occur after the applied treatment modalities. The incidence of RPE tears in PED patients secondary to ARM is reported in 40% of patients treated with PDT and in 26% of patients treated with anti-VEGF.

In the literature, some publications reported a worsening of VA due to the occurrence of an RPE tear after the anti-VEGF injection. Other studies reported no change. However, long-term follow-up of these patients is required and when deciding on the course of treatment to use, possible complications should be considered.

This study has some limitations. The number of patients included in the study was not satisfactory because of the one-year follow-up period and the retreatment indications were not standardized because of the retrospective study design. Indocyanin angiography could not be performed to patients. Furthermore, some of the patients had previously been treated with anti-VEGF drugs. Despite these limitations, this retrospective case series showed that intravitreal anti-VEGF therapy preserved vision and reduced PED height in PED patients in a one-year follow-up period. It is important to note, however, that PED is still difficult to treat and the use of anti-VEGF drugs was not entirely adequate in completing resolving PED in ARM patients. We need prospective large-scale studies on this subject.

REFERENCES